Sprint Bioscience Stock

Sprint Bioscience FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Sprint Bioscience (SPRINT.ST) as of Aug 4, 2026 is 134.89 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -4,661.42 % — a change of -102.89% (higher).

FCF Conversion

134.89 %

YoY

-102.89%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Sprint Bioscience is 2026 134.89 % . FCF Conversion Rate (FCF/EBITDA) of Sprint Bioscience was 2025 -4,661.42 % . It decreases by -102.89% higher compared to the previous year.
Access this data via the Eulerpool API

Sprint Bioscience Stock analysis

What does Sprint Bioscience do? The Swedish company Sprint Bioscience AB is an innovative developer of drugs targeted for use in cancer. The company was founded in Stockholm in 2009 and has since worked with a strong focus on molecular research. Sprint Bioscience is a biotechnology company with the goal of developing drugs for various types of cancer. The company's focus is on so-called "trickster molecules" that can prevent tumor cells from taking up nutrients, ultimately leading to their death. The innovative business model of Sprint Bioscience is that they focus on the discovery and development of molecules, which they then sell to larger pharmaceutical companies that further develop and bring them to market. Sprint Bioscience has a wide range of molecular tools that allow for the identification, development, and optimization of cancer therapy drugs. The company aims to accelerate the discovery of new drugs in the field of oncology. Sprint Bioscience is divided into two business areas: discovery, which specializes in the identification and optimization of drugs for use in cancer, and development, which focuses on the preclinical development of drugs that are later further developed by larger pharmaceutical companies. The most well-known product of Sprint Bioscience is the molecule "SB-11285", a novel cancer therapeutic specifically developed for ovarian cancer. The molecule is intended to help destroy cancer cells by disrupting their cellular metabolism and depriving them of their energy source. Sprint Bioscience has also formed partnerships with other companies to exchange technologies and expertise. For example, there is a collaboration with Bayer to develop new oncology drugs. Overall, Sprint Bioscience has undergone significant development in recent years. The company has built strong expertise in the field of molecular research and effectively implemented its business model. Sprint Bioscience presents itself as a promising player in the biotechnology industry and has the potential to achieve further significant progress in the coming years. Sprint Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sprint Bioscience stock

FCF Conversion Rate (FCF/EBITDA) of Sprint Bioscience is 134.89 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Sprint Bioscience changed from -4,661.42 % to 134.89 %, representing a -102.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Sprint Bioscience since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Sprint Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Sprint Bioscience

All Key Metrics — Sprint Bioscience